This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Picking up post #58: that is the part I would want checked first.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
Adding a source would improve this post and I do not have one to hand.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Not the answer, but possibly the question that gets there.
On dose escalation: the published protocols escalated in defined steps over defined intervals, and those intervals were chosen to manage tolerability. Compressing them is not a small change to the protocol; it is a different protocol.
It is worth stating the boring hypothesis before the interesting one.
Worth separating two things that post #65 runs together.
I would call the community position on retatrutide dose escalation likely rather than established, and I would be comfortable defending that hedge.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
It is worth checking rather than assuming, which costs nothing.
Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.
This has been discussed before and I could not find the thread, so, again.
Answering the question post #68 raises rather than the one it answers.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
Taking post #71 at face value and following it one step further.
Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.
Where I would look next, rather than where I would stop.
I read post #71 twice before replying, because I had assumed the opposite.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
It is one reading of the data and not the only reasonable one.
On retatrutide dose escalation, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Building on post #74 rather than restating it.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
Small point, but it is the one that usually catches people.
The useful distinction on retatrutide dose escalation is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
On post #76 — agreed on the reasoning, with one qualification.
Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.
Reading rather than contributing, but this is the most useful thread I have found on it.
Coming back to post #82, because the follow-up matters more than the original answer.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
The general answer and the answer for your case may diverge here.
The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.
Worth one more sentence than it usually gets.
Post #84 answers the question as asked. The question underneath it is different.
The failure mode on retatrutide dose escalation is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
One more thing on retatrutide dose escalation that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
A modest claim, modestly supported.
Post #86 put the caveat in the right place and I want to underline it.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
If that reads as pedantic, it is, and it has saved me twice.